Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Anti-βc mAb CSL311 inhibits human nasal polyp pathophysiology in a humanized mouse xenograft model.

Yip KH, Wilson NJ, Pant H, Brown CL, Busfield S, Ng M, Alhamdoosh M, Woodman N, Schembri M, Tumes DJ, Vairo G, Lopez AF, Nash AD, Wilson MJ, Grimbaldeston MA, Owczarek CM.

Allergy. 2019 Sep 10. doi: 10.1111/all.14041. [Epub ahead of print] No abstract available.

PMID:
31505024
2.

Role of the β Common (βc) Family of Cytokines in Health and Disease.

Hercus TR, Kan WLT, Broughton SE, Tvorogov D, Ramshaw HS, Sandow JJ, Nero TL, Dhagat U, Thompson EJ, Shing KSCT, McKenzie DR, Wilson NJ, Owczarek CM, Vairo G, Nash AD, Tergaonkar V, Hughes T, Ekert PG, Samuel MS, Bonder CS, Grimbaldeston MA, Parker MW, Lopez AF.

Cold Spring Harb Perspect Biol. 2018 Jun 1;10(6). pii: a028514. doi: 10.1101/cshperspect.a028514. Review.

PMID:
28716883
3.

An Anti-VEGF-B Antibody Fragment Induces Regression of Pre-Existing Blood Vessels in the Rat Cornea.

Irani YD, Scotney PD, Klebe S, Mortimer LA, Nash AD, Williams KA.

Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3404-3413. doi: 10.1167/iovs.16-21343.

PMID:
28692735
4.

Therapeutic Targeting of the G-CSF Receptor Reduces Neutrophil Trafficking and Joint Inflammation in Antibody-Mediated Inflammatory Arthritis.

Campbell IK, Leong D, Edwards KM, Rayzman V, Ng M, Goldberg GL, Wilson NJ, Scalzo-Inguanti K, Mackenzie-Kludas C, Lawlor KE, Wicks IP, Brown LE, Baz Morelli A, Panousis C, Wilson MJ, Nash AD, McKenzie BS, Andrews AE.

J Immunol. 2016 Dec 1;197(11):4392-4402. Epub 2016 Nov 2.

5.

A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosus.

Oon S, Huynh H, Tai TY, Ng M, Monaghan K, Biondo M, Vairo G, Maraskovsky E, Nash AD, Wicks IP, Wilson NJ.

JCI Insight. 2016 May 5;1(6):e86131. doi: 10.1172/jci.insight.86131.

6.

CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors.

Panousis C, Dhagat U, Edwards KM, Rayzman V, Hardy MP, Braley H, Gauvreau GM, Hercus TR, Smith S, Sehmi R, McMillan L, Dottore M, McClure BJ, Fabri LJ, Vairo G, Lopez AF, Parker MW, Nash AD, Wilson NJ, Wilson MJ, Owczarek CM.

MAbs. 2016;8(3):436-53. doi: 10.1080/19420862.2015.1119352. Epub 2015 Dec 14.

7.

Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody.

Broughton SE, Hercus TR, Hardy MP, McClure BJ, Nero TL, Dottore M, Huynh H, Braley H, Barry EF, Kan WL, Dhagat U, Scotney P, Hartman D, Busfield SJ, Owczarek CM, Nash AD, Wilson NJ, Parker MW, Lopez AF.

Cell Rep. 2014 Jul 24;8(2):410-9. doi: 10.1016/j.celrep.2014.06.038. Epub 2014 Jul 17.

8.

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.

Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Ghosh S, Braley H, Panousis C, Roberts AW, He SZ, Thomas D, Fabri L, Vairo G, Lock RB, Lopez AF, Nash AD.

Leukemia. 2014 Nov;28(11):2213-21. doi: 10.1038/leu.2014.128. Epub 2014 Apr 7.

PMID:
24705479
9.

Crystallization and preliminary X-ray diffraction analysis of the interleukin-3 alpha receptor bound to the Fab fragment of antibody CSL362.

Broughton SE, Hercus TR, Nero TL, Dhagat U, Owczarek CM, Hardy MP, Fabri LJ, Scotney PD, Nash AD, Wilson NJ, Lopez AF, Parker MW.

Acta Crystallogr F Struct Biol Commun. 2014 Mar;70(Pt 3):358-61. doi: 10.1107/S2053230X14002593. Epub 2014 Feb 19.

10.

A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.

Larsson M, Rayzman V, Nolte MW, Nickel KF, Björkqvist J, Jämsä A, Hardy MP, Fries M, Schmidbauer S, Hedenqvist P, Broomé M, Pragst I, Dickneite G, Wilson MJ, Nash AD, Panousis C, Renné T.

Sci Transl Med. 2014 Feb 5;6(222):222ra17. doi: 10.1126/scitranslmed.3006804.

11.

Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor α1.

Redpath NT, Xu Y, Wilson NJ, Fabri LJ, Baca M, Andrews AE, Braley H, Lu P, Ireland C, Ernst RE, Woods A, Forrest G, An Z, Zaller DM, Strohl WR, Luo CS, Czabotar PE, Garrett TP, Hilton DJ, Nash AD, Zhang JG, Nicola NA.

Biochem J. 2013 Apr 15;451(2):165-75. doi: 10.1042/BJ20121819.

PMID:
23384096
12.

A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo.

Adams TE, Koziolek EJ, Hoyne PH, Bentley JD, Lu L, Lovrecz G, Ward CW, Lee FT, Scott AM, Nash AD, Rothacker J, Nice EC, Burgess AW, Johns TG.

Growth Factors. 2009 Jun;27(3):141-54. doi: 10.1080/08977190902843565.

PMID:
19333814
13.

Crystal structure of vascular endothelial growth factor-B in complex with a neutralising antibody Fab fragment.

Leonard P, Scotney PD, Jabeen T, Iyer S, Fabri LJ, Nash AD, Acharya KR.

J Mol Biol. 2008 Dec 31;384(5):1203-17. doi: 10.1016/j.jmb.2008.09.076. Epub 2008 Oct 9.

PMID:
18930733
14.

Endogenous IL-11 signaling is essential in Th2- and IL-13-induced inflammation and mucus production.

Lee CG, Hartl D, Matsuura H, Dunlop FM, Scotney PD, Fabri LJ, Nash AD, Chen NY, Tang CY, Chen Q, Homer RJ, Baca M, Elias JA.

Am J Respir Cell Mol Biol. 2008 Dec;39(6):739-46. doi: 10.1165/rcmb.2008-0053OC. Epub 2008 Jul 10.

15.

Crystal structure of human vascular endothelial growth factor-B: identification of amino acids important for receptor binding.

Iyer S, Scotney PD, Nash AD, Ravi Acharya K.

J Mol Biol. 2006 May 26;359(1):76-85. Epub 2006 Apr 17.

PMID:
16616187
16.

The biology of vascular endothelial growth factor-B (VEGF-B).

Nash AD, Baca M, Wright C, Scotney PD.

Pulm Pharmacol Ther. 2006;19(1):61-9. Epub 2005 Apr 25. Review.

PMID:
16286239
17.

SOCS2 negatively regulates growth hormone action in vitro and in vivo.

Greenhalgh CJ, Rico-Bautista E, Lorentzon M, Thaus AL, Morgan PO, Willson TA, Zervoudakis P, Metcalf D, Street I, Nicola NA, Nash AD, Fabri LJ, Norstedt G, Ohlsson C, Flores-Morales A, Alexander WS, Hilton DJ.

J Clin Invest. 2005 Feb;115(2):397-406.

18.

Human vascular endothelial growth factor B: characterization of recombinant isoforms and generation of neutralizing monoclonal antibodies.

Scotney PD, MacKenzie A, Maccarone P, Fabri LJ, Scrofani SD, Gooley PR, Nash AD.

Clin Exp Pharmacol Physiol. 2002 Nov;29(11):1024-9.

PMID:
12366396
19.

Purification and refolding of vascular endothelial growth factor-B.

Scrofani SD, Fabri LJ, Xu P, Maccarone P, Nash AD.

Protein Sci. 2000 Oct;9(10):2018-25.

20.

Isolation and characterization of a novel inducible mammalian galectin.

Dunphy JL, Balic A, Barcham GJ, Horvath AJ, Nash AD, Meeusen EN.

J Biol Chem. 2000 Oct 13;275(41):32106-13.

21.

Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130.

Nicholson SE, De Souza D, Fabri LJ, Corbin J, Willson TA, Zhang JG, Silva A, Asimakis M, Farley A, Nash AD, Metcalf D, Hilton DJ, Nicola NA, Baca M.

Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6493-8.

22.

Cellular requirements for the activation and proliferation of ruminant gammadelta T cells.

Hanrahan CF, Kimpton WG, Howard CJ, Parsons KR, Brandon MR, Andrews AE, Nash AD.

J Immunol. 1997 Nov 1;159(9):4287-94.

PMID:
9379024
23.

A homolog of interleukin-10 is encoded by the poxvirus orf virus.

Fleming SB, McCaughan CA, Andrews AE, Nash AD, Mercer AA.

J Virol. 1997 Jun;71(6):4857-61.

24.

Inflammation-induced changes in the phenotype and cytokine profile of cells migrating through skin and afferent lymph.

Egan PJ, Kimpton W, Seow HF, Bowles VM, Brandon MR, Nash AD.

Immunology. 1996 Dec;89(4):539-46.

25.
26.

Local cell traffic and cytokine production associated with ectoparasite infection.

Nash AD, Egan PJ, Kimpton W, Elhay MJ, Bowles VM.

Vet Immunol Immunopathol. 1996 Nov;54(1-4):269-79. Review.

PMID:
8988873
27.

Vaccination of sheep against larvae of the sheep blowfly (Lucilia cuprina).

Bowles VM, Meeusen EN, Young AR, Andrews AE, Nash AD, Brandon MR.

Vaccine. 1996 Oct;14(14):1347-52.

PMID:
9004444
28.

Follistatin concentrations in male sheep increase following sham castration/castration or injection of interleukin-1 beta.

Phillips DJ, Hedger MP, McFarlane JR, Klein R, Clarke IJ, Tilbrook AJ, Nash AD, de Kretser DM.

J Endocrinol. 1996 Oct;151(1):119-24.

PMID:
8943776
29.

Cytokines as adjuvants for ruminant vaccines.

Lofthouse SA, Andrews AE, Elhay MJ, Bowles VM, Meeusen EN, Nash AD.

Int J Parasitol. 1996 Aug-Sep;26(8-9):835-42. Review.

PMID:
8923133
30.

Parameters related to the application of recombinant ovine interleukin-1 beta as an adjuvant.

Lofthouse SA, Andrews AE, Barcham GJ, Nash AD.

Vaccine. 1995 Oct;13(14):1277-87.

PMID:
8585281
31.

Humoral and cellular responses induced by intradermally administered cytokine and conventional adjuvants.

Lofthouse SA, Andrews AE, Nash AD, Bowles VM.

Vaccine. 1995 Aug;13(12):1131-7.

PMID:
7491821
32.

Cloning and characterisation of an ovine interleukin-10-encoding cDNA.

Martin HM, Nash AD, Andrews AE.

Gene. 1995 Jul 4;159(2):187-91.

PMID:
7622047
33.

Cloning and expression of a cDNA encoding ovine interleukin 7.

Barcham GJ, Andrews AE, Nash AD.

Gene. 1995 Mar 10;154(2):265-9.

PMID:
7890175
34.

Recirculation of cytolytic T cells from a single lymph node during an immune response to allogeneic leukocytes.

Verhagen AM, Kimpton WG, Nash AD.

Transplantation. 1995 Feb 15;59(3):432-5. No abstract available.

PMID:
7871577
35.

Cytokine mRNA expression in skin in response to ectoparasite infection.

Elhay MJ, Hanrahan CF, Bowles VM, Seow HF, Andrews AE, Nash AD.

Parasite Immunol. 1994 Sep;16(9):451-61.

PMID:
7838594
36.

Development of a sandwich immunoassay for the detection of soluble ovine IL-2R alpha chain.

Verhagen AM, Kimpton WG, Nash AD.

Vet Immunol Immunopathol. 1994 Sep;42(3-4):287-300.

PMID:
7528955
37.

Characterization of monoclonal antibodies to ovine tumor necrosis factor-alpha and development of a sensitive immunoassay.

Egan PJ, Rothel JS, Andrews AE, Seow HF, Wood PR, Nash AD.

Vet Immunol Immunopathol. 1994 Jun;41(3-4):259-74.

PMID:
7941307
38.

Production and application of monoclonal antibodies to ovine interleukin-1 alpha and interleukin-1 beta.

Egan PJ, Andrews AE, Barcham GJ, Brandon MR, Nash AD.

Vet Immunol Immunopathol. 1994 Jun;41(3-4):241-57.

PMID:
7524240
39.

The immune response of sheep infected with larvae of the sheep blowfly Lucilia cuprina monitored via efferent lymph.

Bowles VM, Meeusen EN, Chandler K, Verhagen A, Nash AD, Brandon MR.

Vet Immunol Immunopathol. 1994 Apr;40(4):341-52.

PMID:
7913782
40.

Production and in vivo use of recombinant ovine IL-1 beta as an immunological adjuvant.

Andrews AE, Lofthouse SA, Bowles VM, Brandon MR, Nash AD.

Vaccine. 1994 Jan;12(1):14-22.

PMID:
8303935
41.

Recombinant cytokines as immunological adjuvants.

Nash AD, Lofthouse SA, Barcham GJ, Jacobs HJ, Ashman K, Meeusen EN, Brandon MR, Andrews AE.

Immunol Cell Biol. 1993 Oct;71 ( Pt 5):367-79.

PMID:
8270266
42.

Molecular cloning and characterization of a ruminant interleukin-6 cDNA.

Andrews AE, Barcham GJ, Ashman K, Meeusen EN, Brandon MR, Nash AD.

Immunol Cell Biol. 1993 Aug;71 ( Pt 4):341-8.

PMID:
8225400
44.

Molecular cloning, expression and characterization of the ovine IL-2R alpha chain.

Verhagen AM, Andrews AE, Brandon MR, Nash AD.

Immunology. 1992 May;76(1):1-9.

45.

Effects of tumour necrosis factor-alpha on growth hormone and interleukin 6 mRNA in ovine pituitary cells.

Nash AD, Brandon MR, Bello PA.

Mol Cell Endocrinol. 1992 Mar;84(1-2):R31-7.

PMID:
1639212
46.

Characterisation of ovine alveolar macrophages: regulation of surface antigen expression and cytokine production.

Nash AD, Barcham GJ, Andrews AE, Brandon MR.

Vet Immunol Immunopathol. 1992 Feb 15;31(1-2):77-94.

PMID:
1570684
47.

Molecular cloning and characterization of ovine IL-1 alpha and IL-1 beta.

Andrews AE, Barcham GJ, Brandon MR, Nash AD.

Immunology. 1991 Nov;74(3):453-60.

48.

Molecular cloning, expression and characterization of ovine TNF alpha.

Nash AD, Barcham GJ, Brandon MR, Andrews AE.

Immunol Cell Biol. 1991 Aug;69 ( Pt 4):273-83.

PMID:
1786996

Supplemental Content

Support Center